福昕軟件(688095.SH):擬2億元認購江右數科基金份額
格隆匯5月21日丨福昕軟件(688095.SH)公佈,公司擬認購由上海江右私募基金管理有限公司(稱“江右私募”)與深圳市前海恒茂股權投資基金管理有限公司(稱“前海恒茂”)共同作為GP發起設立的江右數科基金份額。該基金預計募集資金總規模為5.02億元(具體金額以實際募集資金為準)。其中,公司擬作為有限合夥人以自有資金認繳出資人民幣2.00億元,認繳出資比例佔總規模的39.84%。
該基金主要圍繞新一代信息技術、數字產業鏈重塑以及“雙碳”背景下的數字化綠色低碳產業等領域,積極佈局包括人工智能、雲計算和雲服務、數據安全、數字孿生、智能交通、智慧能源、數字金融等領域的高新技術企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.